

LEMAITRE VASCULAR INC  
Form 4  
May 26, 2016

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Jasinski Lawrence J

2. Issuer Name and Ticker or Trading Symbol  
LEMAITRE VASCULAR INC  
[LMAT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
05/24/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

BURLINGTON, MA 01803

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |
| Common Stock                    | 05/24/2016                           |  | M                              |   | 1,529<br>(1)  | A  | \$ 6.67 15,642 D                  |
| Common Stock                    | 05/24/2016                           |  | S                              |   | 1,529<br>(2)  | D  | \$ 15.3013 14,113 D               |
| Common Stock                    | 05/24/2016                           |  | S                              |   | 1,435<br>(3)  | D  | \$ 15.3029 12,678 D               |
| Common Stock                    | 05/25/2016                           |  | M                              |   | 2,037<br>(1)  | A  | \$ 6.67 14,715 D                  |

Edgar Filing: LEMAITRE VASCULAR INC - Form 4

|              |            |   |       |   |         |        |   |
|--------------|------------|---|-------|---|---------|--------|---|
| Common Stock | 05/25/2016 | S | 2,037 | D | \$ 15.3 | 12,678 | D |
| Common Stock | 05/25/2016 | S | 1,325 | D | \$ 15.3 | 11,353 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Stock Option (Right to Buy)                | \$ 6.67  | 05/24/2016                           |  | M                              | 1,529   | 07/24/2013 <sup>(4)</sup> 07/24/2018                     | Common Stock  | 1,529                      |
| Stock Option (Right to Buy)                | \$ 6.67  | 05/25/2016                           |  | M                              | 2,037   | 07/24/2013 <sup>(4)</sup> 07/24/2018                     | Common Stock  | 2,037                      |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| Jasinski Lawrence J<br>C/O LEMAITRE VASCULAR, INC.<br>63 SECOND AVENUE<br>BURLINGTON, MA 01803 | X             |           |         |       |

## Signatures

/s/ Laurie Churchill,  
Attorney-in-fact

05/26/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from \$15.30 to

(2) \$15.31. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from \$15.30 to

(3) \$15.32. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

(4) This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the anniversary of the date listed in the table, and the balance vesting in equal annual installments over the remaining two years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.